[go: up one dir, main page]

DE60326053D1 - Superfeine salmeterol zubereitung - Google Patents

Superfeine salmeterol zubereitung

Info

Publication number
DE60326053D1
DE60326053D1 DE60326053T DE60326053T DE60326053D1 DE 60326053 D1 DE60326053 D1 DE 60326053D1 DE 60326053 T DE60326053 T DE 60326053T DE 60326053 T DE60326053 T DE 60326053T DE 60326053 D1 DE60326053 D1 DE 60326053D1
Authority
DE
Germany
Prior art keywords
superfine
salmeterol
preparation
salmeterol preparation
superfine salmeterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60326053T
Other languages
English (en)
Inventor
Tanya Kathleen Church
David Andrew Lewis
David Ganderton
Brian John Meakin
Gaetano Brambilla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32087950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60326053(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Application granted granted Critical
Publication of DE60326053D1 publication Critical patent/DE60326053D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60326053T 2002-10-23 2003-06-18 Superfeine salmeterol zubereitung Expired - Lifetime DE60326053D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02023589A EP1415647A1 (de) 2002-10-23 2002-10-23 Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
PCT/EP2003/006444 WO2004037227A1 (en) 2002-10-23 2003-06-18 Salmeterol superfine formulation

Publications (1)

Publication Number Publication Date
DE60326053D1 true DE60326053D1 (de) 2009-03-19

Family

ID=32087950

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60326053T Expired - Lifetime DE60326053D1 (de) 2002-10-23 2003-06-18 Superfeine salmeterol zubereitung

Country Status (12)

Country Link
US (1) US8088362B2 (de)
EP (2) EP1415647A1 (de)
AR (1) AR040450A1 (de)
AT (1) ATE421875T1 (de)
AU (1) AU2003245965A1 (de)
BR (1) BR0306663A (de)
CA (1) CA2503183C (de)
DE (1) DE60326053D1 (de)
ES (1) ES2319887T3 (de)
NO (1) NO20051956L (de)
PE (1) PE20040314A1 (de)
WO (1) WO2004037227A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
EP1415647A1 (de) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
EP1595531A1 (de) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
WO2008057248A2 (en) * 2006-10-26 2008-05-15 Next Breath Llc Phospholipid-based inhalation system
EP3311820A1 (de) * 2008-02-26 2018-04-25 Sunovion Respiratory Development Inc. Verfahren und system zur behandlung der chronisch obstruktiver lungenerkrankung durch verabreichung zerstäubter anticholinergika
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2440196A4 (de) * 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc Behandlung der chronisch obstruktiven lungenkrankheit mit einem zerstäubten beta-2-agonisten oder durch kombination eines zerstäubten beta-2-agonisten mit der verabreichung von anticholinergika
WO2012007729A2 (en) * 2010-07-16 2012-01-19 Cipla Limited Pharmaceutical compositions
US20230271770A1 (en) * 2020-04-21 2023-08-31 Amphastar Pharmaceuticals, Inc. Anti-Viral Pharmaceutical Formulations Administered Via Devices for Lung Targeted Delivery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
CA2206782C (en) * 1994-12-22 2007-04-03 Astra Aktiebolag Aerosol drug formulations
EP1769819A3 (de) * 1995-04-14 2013-05-22 GlaxoSmithKline LLC Dosierinhalator für Fluticasonepropionat
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
ATE283033T1 (de) * 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US20050048001A1 (en) * 1999-11-23 2005-03-03 Cripps Alan Leslie Pharmaceutical formulations of salmeterol
DE60019167T2 (de) * 1999-12-24 2006-05-11 Glaxo Group Ltd., Greenford Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
IT1318514B1 (it) 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
UA73986C2 (uk) 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
SE0004750D0 (sv) * 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US6455028B1 (en) * 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
SI3494995T1 (sl) 2002-03-01 2020-08-31 Chiesi Farmaceutici S.P.A. Superfina formulacija formoterola
EP1415647A1 (de) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
EP1340492A1 (de) 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren

Also Published As

Publication number Publication date
PE20040314A1 (es) 2004-07-05
BR0306663A (pt) 2004-10-19
ES2319887T3 (es) 2009-05-14
US20060120966A1 (en) 2006-06-08
EP1415647A1 (de) 2004-05-06
AR040450A1 (es) 2005-04-06
CA2503183A1 (en) 2004-05-06
NO20051956D0 (no) 2005-04-21
CA2503183C (en) 2011-06-14
US8088362B2 (en) 2012-01-03
AU2003245965A1 (en) 2004-05-13
EP1553922B1 (de) 2009-01-28
NO20051956L (no) 2005-07-22
WO2004037227A1 (en) 2004-05-06
EP1553922A1 (de) 2005-07-20
ATE421875T1 (de) 2009-02-15

Similar Documents

Publication Publication Date Title
IS7806A (is) Ónæmisvaldandi samsetning
IS7547A (is) Ónæmisvaldandi samsetningar
NO20052914D0 (no) Terapeutiske forbindelser
DE602004031845D1 (de) Ng
NO20050132D0 (no) Vaksinesammensetning
ATE368042T1 (de) Cephemverbindungen
DE10393374D2 (de) Zusammensetzung
IS7381A (is) Efnasambönd
DE60326590D1 (de) Tend lamotrigin
IS7414A (is) Oxó-azabísýklísk efnasambönd
DE60205322D1 (de) Fluoroelastomere
ATE421875T1 (de) Superfeine salmeterol zubereitung
DE50310014D1 (de) Mähbalken
DK1492934T3 (da) Dørenhed
NO20045659L (no) Forbindelser
DE60229463D1 (de) Fluoroelastomere
SE0500163L (sv) Sammansättning
NO20060375L (no) Famasoytisk preparat
DE60304516T8 (de) Fritiergerät
DE60323910D1 (de) Fritiergerät
DE602004018799D1 (de) Ng
DE60328488D1 (de) Ng
EP1561467A4 (de) Zusammensetzung zur wiederherstellung geschädigter haut
NO20043489L (no) Sammensetning for inhalering
NO20044140D0 (no) New Composition

Legal Events

Date Code Title Description
8363 Opposition against the patent